“Interim Safety Results of Amlitelimab (anti-OX40 Ligand Antibody) in Participants With Moderate-to-Severe Atopic Dermatitis From the RIVER-AD Phase 2 3 Ongoing Open-Label Study”. SKIN The Journal of Cutaneous Medicine 9, no. 6 (November 10, 2025): s602. Accessed April 30, 2026. https://skin.dermsquared.com/skin/article/view/3885.